Related references
Note: Only part of the references are listed.Triple-Negative Breast Cancer Role of Specific Chemotherapy Agents
Steven J. Isakoff
CANCER JOURNAL (2010)
The economic burden of breast cancer in California
Wendy Max et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
The Costs of Treating Breast Cancer in the US A Synthesis of Published Evidence
Jonathan D. Campbell et al.
PHARMACOECONOMICS (2009)
Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: Current status and future opportunities
Alison K. Conlin et al.
CLINICAL BREAST CANCER (2008)
Assessing the economic burden of breast cancer in a US managed care population
John J. Barron et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Breast cancer incidence, 1980-2006: Combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status
Andrew G. Glass et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Triple-negative breast cancer: Clinical features and patterns of recurrence
Rebecca Dent et al.
CLINICAL CANCER RESEARCH (2007)
Cost of illness associated with metastatic breast cancer
S Rao et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
C Sotiriou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Repeated observation of breast tumor subtypes in independent gene expression data sets
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
